Pheochromocytoma medical therapy: Difference between revisions
No edit summary |
No edit summary |
||
Line 3: | Line 3: | ||
{{CMG}} {{AE}} {{AAM}} | {{CMG}} {{AE}} {{AAM}} | ||
==Overview== | ==Overview== | ||
The predominant therapy for pheochromocytoma is surgical resection. Treatment with [[phenoxybenzamine]] followed by [[beta blockers]] is required before surgery. | The predominant therapy for pheochromocytoma is surgical resection. Treatment with [[alpha blockers]] (example: [[phenoxybenzamine]]) followed by [[beta blockers]] (example: [[atenolol]]) is required before surgery. | ||
==Medical Therapy== | ==Medical Therapy== |
Revision as of 19:25, 2 September 2015
Pheochromocytoma Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Pheochromocytoma medical therapy On the Web |
American Roentgen Ray Society Images of Pheochromocytoma medical therapy |
Risk calculators and risk factors for Pheochromocytoma medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Ahmad Al Maradni, M.D. [2]
Overview
The predominant therapy for pheochromocytoma is surgical resection. Treatment with alpha blockers (example: phenoxybenzamine) followed by beta blockers (example: atenolol) is required before surgery.
Medical Therapy
Any surgical option requires prior treatment with both the non-specific alpha adrenoceptor blocker phenoxybenzamine to counteract hypertension and the beta-1 adrenoceptor antagonist atenolol to reduce cardiac output. Given before surgery, these can also block the effect of a sudden release of adrenaline during tumour removal, which would otherwise endanger the anaethetised patient.
Contraindicated medications
Pheochromocytoma is considered an absolute contraindication to the use of the following medications: